Chinese firm says coronavirus vaccine candidate shows promise in human test

  • Chinese firm says coronavirus vaccine candidate shows promise in human test

Chinese firm says coronavirus vaccine candidate shows promise in human test

Over the weekend, Sinopharm Group announced that in partnership with the Chinese Centre for Disease Control and Prevention, they are advancing on clinical trials to develop a COVID-19 vaccine.

It is not clear which of CNBG's Covid-19 vaccine candidates will be tested in the phase-3 trial in the UAE.

China's Central Military Commission approved the use of the vaccine by the military on June 25 for a period of one year, CanSino said in a filing.

A Covid-19 vaccine candidate developed by a Beijing unit of China National Biotec Group (CNBG) has shown positive results in early human trials, the company said on Sunday.

CanSino said Ad5-nCoV is now restricted to military use only.

"The Ad5-nCoV is now limited to military use only and its use can not be expanded to a broader vaccination range without the approval of the Logistics Support Department", CanSino said, referring to the Central Military Commission department where the military use of the vaccine was approved.

Ad5-nCoV was among the country's leading candidates for coronavirus vaccine for quite some time.

According to medical journal The Lancet there have already been more than 1,000 clinical trials on dozens of pharmaceutical treatments for the virus but no totally effective medical intervention has been found.

The experimental shot, developed by a Beijing-based unit of CNBG, has induced high-level antibodies in all the inoculated participants in a Phase 1/2 clinical trial involving 1,120 healthy people, according to preliminary data of the trial, CNBG said in a posting on the social media platform WeChat, without disclosing specific readings.

None have yet been approved for commercial use against the coronavirus. The vaccine will prove to be a breakthrough to contain spread of Covid-19. The pandemic has so far affected over 10,000,000 people globally and claimed more than 500,000 lives.